Portal de investigación
- Inicio
- Proyectos y Estudios
- ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PALBOCICLIB (PD0332991), UN INHIBIDOR DE LAS CICLINAS DEPENDIENTES DE KINASAS 4 Y 6 (CDK4 Y CDK6), EN PACIENTES CON OLIGODENDROGLIOMA RECURRENTE CON PRESERVACIÓN DE LA ACTIVIDAD DE LA PROTEÍNA RB.
ENSAYO CLÍNICO FASE II PILOTO, ABIERTO, MULTICÉNTRICO Y PROSPECTIVO PARA EVALUAR LA SEGURIDAD Y EFICACIA DE PALBOCICLIB (PD0332991), UN INHIBIDOR DE LAS CICLINAS DEPENDIENTES DE KINASAS 4 Y 6 (CDK4 Y CDK6), EN PACIENTES CON OLIGODENDROGLIOMA RECURRENTE CON PRESERVACIÓN DE LA ACTIVIDAD DE LA PROTEÍNA RB.
Datos básicos
- Protocolo:
- GEINO-13
- EUDRACT:
- 2015-001722-42
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Año de incio:
- 2017
- Año de finalización:
Documentos
- No hay documentos
Participantes
Financiadores - Promotores
Resultados del Ensayo Clínico
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01).
Balana C; (...); Carrato C
Article. 10.1093/neuonc/noaa107. 2020
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib
Diaz-Beveridge, R; (...); Aparicio, J
Article. 10.1007/s12094-017-1720-4. 2018
Baseline circulating myeloid-derived suppressor cells subpopulations, neutrophils/lymphocytes ratio, and response to PD-1/PD-L1 inhibitor in non-small cell lung cancer patients.
SAnchez, JosE GarcIa; (...); Lahoz, Agustin
Meeting Abstract. 2020
Characterization of thrombosis risk in patients with cancer
Cerezuela, P; (...); Trujillo-Santos, J
Meeting Abstract. 10.1016/j.thromres.2018.02.121. 2018
Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations
Salvador-Coloma, C; (...); Juan, O
Article. 10.21037/jtd.2018.02.30. 2018
Immune-related adverse events (irAEs) and survival (OS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with immunotherapy
Melian Sosa, M.; (...); Lorente, D.
Meeting Abstract. 2018
Long-Term Survival for Brain-Only Oligometastatic NSCLC Patients Treated with Ablative Therapy (AT): Prognostic Factors
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment
Melian, M; (...); Juan, O
Article. 10.1111/1759-7714.12873. 2018
Lymphoscintigraphic findings in patients with lipedema
Forner-Cordero, I; (...); Munoz-Langa, J
Article. 10.1016/j.remn.2018.06.008. 2018
Lymphoscintigraphic findings in patients with lipedema
Olivan-Sasot, P; (...); Bello-Arques, P
Meeting Abstract. 2017
Multi-parametric MR Imaging Biomarkers Associated to Clinical Outcomes in Gliomas: A Systematic Review.
Oltra-Sastre M; (...); Garcia-Gomez JM
Article. 10.2174/1573405615666190109100503. 2019
Preliminarily results of the Oncohabitats Study: A multicentre validation of overall survival (OS) estimation of patients with glioblastoma (GBM) using vascular biomarkers
Alvarez-Torres, MD; (...); Garcia-Gomez, JM
Meeting Abstract. 10.1158/1538-7445.AM2019-4258. 2019
Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
Vidal, OJJ; (...); Palanca, S
Meeting Abstract. 2019
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC)
Juan, O; (...); Codina, JG
Meeting Abstract. 10.1016/S1556-0864(18)30411-8. 2018
Prognostic factors in oligometastatic non-small-cell lung cancer (OM-NSCLC) patients treated with ablative therapy.
Antonio Mendez, Juan; (...); Juan Vidal, Oscar
Meeting Abstract. 10.1200/JCO.2018.36.15_suppl.e21089. 2018
Quantitative assessment is essential for interpreting lymphoscintigraphy: Response to Ramin Sadeghi's letter to the editor
Forner-Cordero, I; (...); Munoz-Langa, J
Letter. 10.1016/j.remn.2018.12.003. 2019
Risk assessment in brain-only oligometastatic non-small cell lung cancer (BOO-NSCLC) patients (pts): Recursive partioning analysis (RPA) model modification
Salvador Coloma, C.; (...); Juan-Vidal, O.
Meeting Abstract. 2018
Robust association between vascular habitats and patient prognosis in glioblastoma: An international multicenter study.
Álvarez-Torres MDM; (...); García-Gómez JM
Article. 10.1002/jmri.26958. 2020
SEOM clinical guideline of diagnosis and management of low-grade glioma (2017)
Sepulveda-Sanchez, JM; (...); Gallego, O
Article. 10.1007/s12094-017-1790-3. 2018
SEOM clinical guideline of diagnosis and management of low-grade glioma (vol 20, pg 3, 2017)
Sepulveda-Sanchez, JM; (...); Gallego, O
Correction. 10.1007/s12094-017-1814-z. 2018
Various Clinical Scenarios in Secondary Malignant Lymphedema.
Forner-Cordero, I; (...); Munoz-Langa, J
Article. 2022